异基因移植和嵌合抗原受体修饰 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Mail Stop D3-100, Seattle, WA 98109, USA; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Mail Stop D3-100, Seattle, WA 98109, USA; Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
出版信息
Hematol Oncol Clin North Am. 2020 Oct;34(5):957-970. doi: 10.1016/j.hoc.2020.06.010. Epub 2020 Aug 1.
Mantle cell lymphoma (MCL) accounts for fewer than 10% of non-Hodgkin lymphoma. There is a high initial response rate to chemotherapy and rituximab, but a nearly universal risk of relapse. Allogeneic hematopoietic cell transplantation (allo-HCT) provides one of the only curative options. We review the role of allo-HCT for relapsed and refractory (R/R) MCL and discuss a novel promising approach using autologous chimeric antigen receptor-engineered T (CAR-T) cells. We review preliminary safety and efficacy data of 2 pivotal trials investigating the use of CD19-targeted CAR-T cells for R/R MCL after ibrutinib failure and discuss potential timing of these approaches.
套细胞淋巴瘤（MCL）占非霍奇金淋巴瘤的比例不到 10%。化疗和利妥昔单抗初始反应率高，但几乎普遍存在复发风险。异基因造血细胞移植（allo-HCT）是唯一的治愈选择之一。我们回顾了 allo-HCT 治疗复发和难治性（R/R）MCL 的作用，并讨论了使用自体嵌合抗原受体修饰 T（CAR-T）细胞的一种新的有前途的方法。我们回顾了 2 项关键性试验的初步安全性和疗效数据，这些试验调查了在伊布替尼治疗失败后，针对 R/R MCL 使用靶向 CD19 的 CAR-T 细胞的应用，并讨论了这些方法的潜在时机。
Zotero 插件